ABSTRACT
Transcriptomic studies lend insight into the biology of genetic regulation and bear promise in furthering the goals of precision medicine. However, the cost of RNA-sequencing and types of tissues currently assayed pose major limitations to study expansion and disease-relevant discovery. Here, we develop methods for sampling noninvasive biospecimens for transcriptome studies, investigate their technical and biological characteristics, and assess the feasibility of using noninvasive samples in transcriptomic and clinical applications. Of the four tissues we studied (buccal swabs, hair follicles, saliva, and urine cell pellets), we found hair follicles and urine cell pellets to be most promising due to the consistency of sample quality, underlying biology, and capture of disease-relevant signals. We anticipate future use of noninvasive sampling will facilitate discovery by increasing sample sizes in more diverse populations and in tissues with greater cell type diversity and biological relatedness to disease mechanisms. Moreover, the nature of noninvasive samples enables complex study designs with greater ability to capture context-dependent mechanisms of genetic regulation.
Competing Interest Statement
T.L. advises and has equity in Variant Bio, and advises Goldfinch Bio. and GSK. S.E.C. is a cofounder, chief technology officer, and stock owner at Variant Bio.